Sign up to save your podcasts
Or
Share Unusual Clinical Presentation of BCell Prolymphocytic Leukemia Cases as Splenic Marginal Zone Lymphoma Effectively Treated With Rituximab Monotherapy summary
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Unusual Clinical Presentation of BCell Prolymphocytic Leukemia Cases as Splenic Marginal Zone Lymphoma Effectively Treated With Rituximab Monotherapy summary
In this PACULit episode, Britany and Seth discuss Sachanas et al.'s August 2025 study on B-cell prolymphocytic leukemia cases that mimic splenic marginal zone lymphoma. The hosts review how SMZL-like biology can occur within B-PLL phenotypes, evaluate Rituximab monotherapy as a safer alternative to chemotherapy or splenectomy, and emphasize the importance of comprehensive immunophenotyping and cytogenetics to guide therapy. Key findings include complete remission in 40% and prolonged responses in 80%, the relevance of 7q deletions, and the study's limitations and implications for future guidelines and personalized treatment in older or frail patients.
View all episodes
By Pharmacy & Acute Care UniversityIn this PACULit episode, Britany and Seth discuss Sachanas et al.'s August 2025 study on B-cell prolymphocytic leukemia cases that mimic splenic marginal zone lymphoma. The hosts review how SMZL-like biology can occur within B-PLL phenotypes, evaluate Rituximab monotherapy as a safer alternative to chemotherapy or splenectomy, and emphasize the importance of comprehensive immunophenotyping and cytogenetics to guide therapy. Key findings include complete remission in 40% and prolonged responses in 80%, the relevance of 7q deletions, and the study's limitations and implications for future guidelines and personalized treatment in older or frail patients.